Prenatal diagnosis and postnatal outcomes of cavum septum pellucidum et vergae

Year 2024, Volume: 3 Issue: 3, 107 - 111, 27.09.2024

Hakkı Şerbetçi , Atakan Tanacan , Refaettin Şahin , Osman Onur Özkavak , Murat Haksever , Mehmet Utku Başarır , Özgür Kara , Dilek Sahin

https://doi.org/10.5505/achmedj.2024.43534

Abstract

Introductıon: Evaluation of demographic characteristics and postnatal outcomes of fetuses with cavum septum pellucidum et vergae (CSPV) diagnosis followed in a tertiary center.
Methods: This retrospective study was conducted in Ankara Bilkent City Hospital perinatology clinic between 2020-2023. Cases with the prenatal diagnosis of CSPV were evaluated. Demographic features, prenatal ultrasound findings, noninvasive screening test results, invasive diagnostic test results, prenatal anomaly screening ultrasound findings, and postnatal outcomes were reported.
Results: There was a total of 24 prenatally diagnosed CSPV cases during the study period. The mean gestational week at diagnosis was 25.6 ± 3.2 weeks. Nineteen patients participated in noninvasive screening tests; five patients declined them. Noninvasive screening tests revealed low risk in 17 patients and high risk in 2. Amniocentesis was performed in 5 patients; 3 of them had a normal karyotype, 1 fetus was diagnosed with Smith-Lemli-Opitz syndrome, and 1 fetus had trisomy 21. Six patients with isolated CSPV were accepted and underwent fetal MRI, other eighteen patients refused MRI. MRI corrected the CSPV in all six patients, and they had no additional findings. Five (%21) fetuses were admitted to the intensive care unit because of recurrent absence convulsions (n=1), anal atresia (n=1), cleft lip palate (n=1), respiratory distress (n=1) and hypoplastic left heart syndrome (n=1).
Conclusion: CSPV is considered a normal variant of cavum septum pellucidum and can be diagnosed during ultrasound screening for fetal anomalies; in isolated cases perinatal outcomes are favorable.

Keywords

Cavum septum pellucidum et vergae, Pregnancy, Central nervous system, Postnatal outcome, Perinatology

References

• 1. Nakajima Y, Yano S, Kuramatsu T, Ichihashi K, Miyao M, Yanagisawa M, et al. Ultrasonographic evaluation of cavum septi pellucidi and cavum vergae. Brain Dev. 1986;8(5):505–8.
• 2. Sarwar M. The septum pellucidum: normal and abnormal. Am J Neuroradiol. 1989;10(5):989–1005.
• 3. Rakic P, Yakovlev PI. Development of the corpus callosum and cavum septi in man. J Comp Neurol. 1968;132(1):45–72.
• 4. Winter TC, Kennedy AM, Byrne J, Woodward PJ. The cavum septi pellucidi: why is it important? J Ultrasound Med. 2010;29(3):427–44.
• 5. Malinger G, Lev D, Kidron D, Heredia F, Hershkovitz R, Lerman‐Sagie T. Differential diagnosis in fetuses with absent septum pellucidum. Ultrasound Obstet Gynecol Off J Int Soc Ultrasound Obstet Gynecol. 2005;25(1):42–9.
• 6. Sitoh Y-Y, Tien RD. The limbic system. An overview of the anatomy and its development. Neuroimaging Clin N Am. 1997;7(1):1–10.
• 7. Mott SH, Bodensteiner JB, Allan WC. The cavum septi pellucidi in term and preterm newborn infants. J Child Neurol. 1992;7(1):35–8.
• 8. Pilu G, Sandri F, Perolo A, Pittalis MC, Grisolia G, Cocchi G, et al. Sonography of fetal agenesis of the corpus callosum: a survey of 35 cases. Ultrasound Obstet Gynecol Off J Int Soc Ultrasound Obstet Gynecol. 1993;3(5):318–29.
• 9. Jou H, Shyu M, Wu S, Chen S, Su C, Hsieh F. Ultrasound measurement of the fetal cavum septi pellucidi. Ultrasound Obstet Gynecol Off J Int Soc Ultrasound Obstet Gynecol. 1998;12(6):419–21.
• 10. Tao G, Lu G, Zhan X, Li J, Cheng L, Lee K, et al. Sonographic appearance of the cavum septum pellucidum et vergae in normal fetuses in the second and third trimesters of pregnancy. J Clin Ultrasound. 2013;41(9):525–31.
• 11. BRONSHTEIN M, WEINER Z. Prenatal diagnosis of dilated cava septi pellucidi et vergae: associated anomalies, differential diagnosis, and pregnancy outcome. Obstet Gynecol. 1992;80(5):838–42.
• 12. Bohm LA, Zhou TC, Mingo TJ, Dugan SL, Patterson RJ, Sidman JD, et al. Neuroradiographic findings in 22q11. 2 deletion syndrome. Am J Med Genet Part A. 2017;173(8):2158–65.
• 13. Karl K, Esser T, Heling KS, Chaoui R. Cavum septi pellucidi (CSP) ratio: a marker for partial agenesis of the fetal corpus callosum. Ultrasound Obstet Gynecol. 2017;50(3):336–41.